Market Overview

Celgene Announces Updated Data from Phase IIIb MAGNIFY Study of REVLIMID and Rituximab Combination (R2) Show Clinical Activity and Responses in Relapsed/Refractory Follicular and MZL

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News

 

Related Articles (CELG)